# Efficacy and Safety of HCP1102 Capsule in Patients With Perennial Allergic Rhinitis

> **NCT04324918** · PHASE3 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 174 (actual)

## Conditions studied

- Perennial Allergic Rhinitis

## Interventions

- **DRUG:** HCP1102
- **DRUG:** HGP1408

## Key facts

- **NCT ID:** NCT04324918
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-23
- **Primary completion:** 2019-06-24
- **Final completion:** 2019-06-24
- **Target enrollment:** 174 (ACTUAL)
- **Last updated:** 2020-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04324918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04324918, "Efficacy and Safety of HCP1102 Capsule in Patients With Perennial Allergic Rhinitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04324918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*